Clinical trials recruiting in Orlando, Florida

Phase breakdown

Conditions recruiting in Orlando, Florida

Recruiting trials in Orlando, Florida

• A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
  NCT07227597 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
  NCT07266831 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
  NCT07033494 · Phase: Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female)
• A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
  NCT07044297 · Phase: Phase 3 · Ages: 16 Years and older · Sex: All (male and female)
• A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
  NCT07218029 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
  NCT07348237 · Phase: Phase 1 · Ages: 24 Years to 85 Years · Sex: All (male and female)
• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07170150 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female)
• A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
  NCT07186842 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
  NCT06872125 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female)
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
  NCT05211895 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
  NCT05986292 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
  NCT06143956 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
  NCT07165028 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
  NCT05932862 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
  NCT06150664 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
  NCT07109726 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
  NCT06625671 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
  NCT06680830 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
  NCT06830629 · Phase: Phase 2 · Ages: 18 Years to 68 Years · Sex: All (male and female)
• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
  NCT06695845 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
  NCT06226883 · Phase: Phase 2 · Ages: 18 Years to 85 Years · Sex: All (male and female)
• A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
  NCT07113522 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
  NCT07202546 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
  NCT07011745 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
  NCT07011732 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
  NCT07592689 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female)
• A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
  NCT06660394 · Phase: Phase 3 · Ages: 2 Years to 65 Years · Sex: All (male and female)
• A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
  NCT05862272 · Phase: Phase 3 · Ages: 18 Years to 50 Years · Sex: Female
• A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
  NCT06792552 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
  NCT06906562 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
  NCT07662044 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
  NCT07662135 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
  NCT06672549 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female)
• A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
  NCT05519475 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
  NCT03887715 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
  NCT06992258 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
  NCT07172516 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female)
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
  NCT06775379 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female)
• A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
  NCT06979362 · Phase: Phase 2 · Ages: 40 Years to 84 Years · Sex: All (male and female)
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
  NCT07491172 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System
  NCT07227532 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years and older · Sex: All (male and female)
• A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
  NCT06528314 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
  NCT06215716 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
  NCT06433752 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
  NCT05800665 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male
• A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
  NCT05076175 · Phase: Phase 2, Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female)
• A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
  NCT05995964 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
  NCT06586957 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
  NCT06285643 · Phase: Phase 2 · Ages: 45 Years to 75 Years · Sex: All (male and female)
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
  NCT06750094 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
  NCT06662786 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT06667076 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
  NCT05498428 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)
  NCT06455098 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
  NCT06706076 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
  NCT03526835 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
  NCT07286175 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Brenipatide in Adult Participants With Major Depressive Disorder
  NCT07412756 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Brenipatide in Adult Participants With Schizophrenia
  NCT07410507 · Phase: Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female)
• A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
  NCT07041099 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
  NCT06613360 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
  NCT06765668 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study of DB-1310 in Advanced/Metastatic Solid Tumors
  NCT05785741 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
  NCT06999187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
  NCT07602582 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female)
• A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
  NCT07589595 · Phase: Phase 2 · Ages: 55 Years to 85 Years · Sex: All (male and female)
• A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
  NCT06739122 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female)
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
  NCT06492616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
  NCT06598943 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
  NCT06119581 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
  NCT06362252 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
  NCT07174583 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
  NCT07277413 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
  NCT06203210 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
  NCT06077760 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
  NCT06667908 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
  NCT07323654 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of LY3439539 in Participants With Alzheimer's Disease
  NCT07598370 · Phase: Phase 1 · Ages: 50 Years to 85 Years · Sex: All (male and female)
• A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
  NCT06809400 · Phase: Phase 1 · Ages: 30 Years to 85 Years · Sex: All (male and female)
• A Study of LY4175408 in Participants With Advanced Cancer
  NCT07046923 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
  NCT07142356 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)
  NCT07575932 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
  NCT06914128 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT07225946 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
  NCT07268638 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
  NCT06131840 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
  NCT06312176 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
  NCT06841354 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors
  NCT04389632 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
  NCT06045754 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
  NCT06095128 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
  NCT06227910 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
  NCT06581328 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
  NCT06671483 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
  NCT07020117 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)

Showing 100 of 358 recruiting trials.

Common questions

How many clinical trials are recruiting in Orlando, Florida?

358 recruiting trials have at least one study site in Orlando, Florida.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.